Primary Risk Drivers
Below is a snapshot of domains that materially influence the MARA Rating.
Clinical effectiveness
The clinical effectiveness of tradipitant is supported by two Phase 3 randomized controlled trials (RCTs) demonstrating significant reductions in vomiting incidence compared to placebo. In Study 1, the incidence was 20% for the 85 mg dose and 18% for the 170 mg dose versus 44% for placebo. Study 2 showed similar results with 18% and 10% for tradipitant versus 38% for placebo. However, secondary endpoints related to nausea did not reach statistical significance, indicating a moderate benefit overall.
Cost effectiveness
No cost-utility analyses or incremental cost-effectiveness ratios (ICERs) specific to tradipitant for motion-sickness vomiting were identified. The absence of economic models and cost data indicates a lack of evidence for cost-effectiveness, leading to a non-cost-effective classification.
Quality of life
There is no evidence of generic utility-based HRQoL measures (e.g., EQ-5D) reported in the FDA label or trial publications. The available symptom instruments do not provide a comprehensive view of HRQoL, and no caregiver outcomes were identified, leading to a potential decline in quality of life due to treatment burden.
Supporting Domains
Safety and Adverse Effects
Tradipitant has an acceptable safety profile with primarily mild to moderate adverse effects such as somnolence, headache, and fatigue. The adverse events reported are consistent with those expected for a neurokinin-1 receptor antagonist, and the safety data from the trials indicate manageable risks.
Comparator Selection
The pivotal studies used placebo comparators rather than active standard-of-care agents like scopolamine or antihistamines. While placebo comparisons are acceptable for establishing efficacy, they limit the relevance of the findings for patients already using existing therapies.
Patient Population and Subgroups
The trial population is described with demographic details, and subgroup analyses by sex and age were conducted. However, generalizability to broader populations, especially pediatric patients, is limited due to the exclusion criteria and the focus on adults.
Care Pathway Integration
Tradipitant can be easily integrated into existing care pathways as it requires no specialized diagnostics or extensive training. The treatment is positioned as a pre-exposure preventive measure, aligning well with current clinical practices.
Resource Use and Cost Implications
There is a lack of data on direct medical costs, implementation costs, and potential cost savings from avoided events. The absence of economic evaluations and variability across settings raises concerns about the resource implications of adopting tradipitant.
Evidence Quality and Robustness
The evidence is based on well-designed Phase 3 RCTs with clear primary endpoints and rigorous methodologies. However, concerns about indirectness due to the use of placebo comparators limit the external validity of the findings.
Uncertainty, Sensitivity, and Broader Impacts
While clinical uncertainty is quantified through confidence intervals and p-values, there is significant uncertainty regarding the broader impacts, including equity and access considerations, particularly for pediatric populations. The lack of data on long-term outcomes further contributes to this uncertainty.
